In a systematic review and meta-analysis, statin plus EPA therapy led to greater percent and absolute reductions in total and lipid plaque volumes compared with statin only, while statin plus EPA/DHA therapy had no effect.

Prof. Leiter presents a case of a patient with high CV risk despite LDL-c lowering with statin therapy. He explains why this patient may benefit from treatment with icosapent ethyl.

At the end of AHA 2022, an international expert panel discusses the latest results of trials with pemafibrate and EPA. What do these findings mean for management of patients in clinical practice?

In a REDUCE-IT substudy, icosapent ethyl had little to no effect on biomarkers associated with atherosclerotic disease, such as IL-1β, IL-6, oxidized LDL-c, and Lp(a). However, mineral oil increased these levels.

AHA 2022 The RESPECT-EPA study evaluated the effects of highly purified EPA in combination with statin therapy on CV events in Japanese patients with chronic CAD.

REDUCE-IT showed that icosapent ethyl (IPE) lowers the risk of ischemic events by 25% in high-risk patients with hypertriglyceridemia already receiving statin therapy. But can IPE also reduce the risk of ischemic events attributable to smoking in these patients?

In this presentation, Prof. Subodh Verma presents 11 clinical implications of the REDUCE-IT trial with icosapent ethyl.

What are potential mechanisms that may explain the benefits observed with icosapent ethyl? Prof. Bäck discusses three mechanisms: TG lowering, anti-thrombotic effects, and resolution of inflammation.

It has been 3 years since the presentation and publication of the REDUCE-IT trial. What are more recent insights from subsequent analyses of the REDUCE-IT trial?

ESC 2022 An analysis of the REDUCE-IT trial showed that use of icosapent ethyl reduces the rate of MI overall, and of MI subtypes including STEMI, NSTEMI, MI leading to cardiac arrest and resuscitated MI, when compared to placebo.

After presenting findings from the REDUCE-IT trial, prof. Packard discusses the place for icosapent ethyl. He talks about the need for a tailored approach in ASCVD patients with high risk.

NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.